Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient

A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estr...

Descripción completa

Detalles Bibliográficos
Autor principal: Morita, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658217/
https://www.ncbi.nlm.nih.gov/pubmed/23754886
_version_ 1782270232340987904
author Morita, Tatsuo
author_facet Morita, Tatsuo
author_sort Morita, Tatsuo
collection PubMed
description A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estramustine phosphate (EMP) because of the progression to hormone-refractory prostate cancer (HRPC). Leukocytosis over 20000/μL was repeatedly observed at each administration of EMP. This is the first case report of leukocytosis in response to EMP in an HRPC patient. The present case suggests that EMP could modulate leukocyte differentiation in HRPC patients.
format Online
Article
Text
id pubmed-3658217
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36582172013-06-10 Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient Morita, Tatsuo Int Med Case Rep J Case Report A 67-year-old man was refered to our institution with a complaint of elevated serum prostate-specific antigen (PSA) level (54 ng/mL). Diagnosis was adenocarcinoma of the prostate with a Gleason score of 9, with bone metastasis (stageD2). He was treated with maximal androgen blockade followed by estramustine phosphate (EMP) because of the progression to hormone-refractory prostate cancer (HRPC). Leukocytosis over 20000/μL was repeatedly observed at each administration of EMP. This is the first case report of leukocytosis in response to EMP in an HRPC patient. The present case suggests that EMP could modulate leukocyte differentiation in HRPC patients. Dove Medical Press 2010-04-19 /pmc/articles/PMC3658217/ /pubmed/23754886 Text en © 2010 Morita, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Report
Morita, Tatsuo
Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
title Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
title_full Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
title_fullStr Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
title_full_unstemmed Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
title_short Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
title_sort marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658217/
https://www.ncbi.nlm.nih.gov/pubmed/23754886
work_keys_str_mv AT moritatatsuo markedleukocytosisinresponsetoestramustinephosphateinahormonerefractoryprostatecancerpatient

Ejemplares similares